Anicet Okinga is the new Pharmaceutical Patent Senior Advisor at Licks Attorneys

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Anicet Okinga is the new Pharmaceutical Patent Senior Advisor at Licks Attorneys

Sponsored by

Licks_Brazil.png

Licks Attorneys announce Anicet Okinga as the new Pharmaceutical Patent Senior Advisor at Licks Attorneys

Licks Attorneys is pleased to announce the hiring of Prof. Dr. Anicet Okinga, DDS Oral and Dental Surgeon, PharmD, Doctor in Pharmaceutical Sciences, as the firm’s new Pharmaceutical Patents Senior Advisor. His arrival reinforces the firm’s strategic focus on scientific excellence, high complexity patent matters, and technical depth in the pharmaceutical sector.

Prof. Dr. Okinga brings a multidisciplinary background that spans dentistry, pharmacy, and advanced research in clinical and experimental pathophysiology. His scientific experience includes work in pharmacology, neuroscience, inflammation, metabolism, and bioactive compounds—knowledge that strengthens the firm’s ability to support clients in highly technical patent disputes and prosecution strategies.

From 2017 to 2026, he served as a Patent Examiner in the Pharmaceuticals Art Unit at the Brazilian Patent and Trademark Office (BRPTO), where he conducted substantive examination of applications involving pharmaceutical compounds, formulations, delivery systems, and medical uses. His perspective as a former examiner adds a valuable regulatory and procedural dimension to the team’s work, supporting informed and effective strategies for innovation driven clients.

His training includes the Cycle Long “Brevets d’invention” at the Université de Strasbourg (UNISTRA) and advanced programs from WIPO, the EPO, and the European Patent Academy, with focus on patent drafting, examination procedures, unity of invention, and European patent law.

Beyond his technical background, Prof. Dr. Okinga has contributed to governance and diversity initiatives, serving as Honorary Counselor at the State Council for the Rights of Black People and the Promotion of Racial Equality in Rio de Janeiro (CEDINE RJ) and collaborating with the Racial Equality Commission of the Brazilian Bar Association (OAB/RJ). He also chaired the BRPTO Careers and Positions Commission between 2021 and 2023 and holds a LideraGov 4.0 certification for innovation oriented public leadership.

Anicet Okinga arrival strengthens Licks Attorneys’ capacity to navigate the intersection of science, regulation, and intellectual property, offering clients a deeper technical foundation in pharmaceutical innovation and patent protection.

more from across site and SHARED ros bottom lb

More from across our site

Fresh off a string of ITC victories, Latham has recruited Baker Botts’ ITC leader Lisa Kattan, adding another prominent name to one of the market's busiest ITC practices
The firm hopes its recent Düsseldorf expansion and UK partner hire will strengthen its offering as it looks to an integrated model to boost UPC capabilities
Stephenson Harwood’s trademark prosecution push and patent ambitions could complement Taylor Wessing’s remaining but depleted European IP strength following its UK arm’s departure
Gerben IP’s first woman partner, Sophie Edbrooke, explains how boutique life allowed her to broaden her expertise, take on leadership responsibilities and carve out a route to the top
INTA has a right to protect its Annual Meeting, but making it harder for others to hold similar events risks leaving delegates with a bigger travel bill
The firm says it hopes to capture patent litigation work in Texas by arming itself with experienced trial lawyers with venue expertise
Ken Iijima's arrival continues a trend of ex-Pizzeys practitioners joining RnB IP, whose co-founder says independent ownership and a lucrative compensation model have become attractive in a consolidating market
McDermott Will & Schulte lawyers explore why the UPC is seeing rapid adoption by medtech for fast-moving disputes, while pharma and biotech take a cautious, selective approach over revocation risks
IP firms may be growing more comfortable with external capital, but uncertainty over who could ultimately own the business is complicating the investment pitch
The former Western District of Texas judge addresses perceptions of his courtroom, reveals what comes next as he returns to practice at A&O Shearman and explains why marathon running is ‘cathartic’
Gift this article